Accelerating Cancer Immunotherapy 2017: Multimedia


Please click on the presentation title to view the multimedia, or click on the speaker name to view their bio.

Wednesday Morning

Scientific Session 1

09:00
Eradicating tumors using the immune system
Professor Robert Schreiber, PhD
Alumni Professor, Pathology and Immunology, Director, Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, MO. USA


09.30
Immune checkpoint in cancer therapy:  New insights into mechanism
Dr James P. Allison
Department Chair, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


10.00
From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
Dr Padmanee Sharma
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


12:00
The affordability of the extraordinary
Professor Richard Sullivan
Director of the Institute of Cancer Policy and King’s Health Partners Integrated Cancer Centre Global Health Work, London, UK


Thursday Afternoon

Scientific Session 2

14:30
Targeting the cancer mutanome
Dr Alena Gros Vidal
Group Leader, Vall d’Hebron Institute of Oncology, Barcelona, Spain


15.30
Radiation treatment and immunotherapy combinations to improve outcome for cancer patients
Professor Tim Illidge
Professor of Targeted Therapy and Oncology, Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK


16.30
The tumor microenvironment and the dynamics of the immune response in human tumors
Dr Jerome Galon
Research Director, Integrative Cancer Immunology Laboratory, INSERM, Paris, France


Thursday Morning

Scientific Session 3 with The Lancet Oncology

08:30
Trends & Collaborations in the IO Space
Dr Ramy Ibrahim
VP and Head of R&D, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA

09.00
Deciphering immune regulation and recognition at the tumour site
Dr Sergio Quezada
Head of the Immune Regulation and Tumour Immunotherapy group, UCL Cancer Institute, London, UK

09.30
Immune biomarkers and measuring response
Professor Alexander MM Eggermont
Director General of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

10.00
Immuno-oncolytic viruses as cancer therapies
Professor Alan Melcher
Professor of Translational Immunotherapy; Team Leader, Translational Immunotherapy Team, The Institute of Cancer Research, London, UK


Thursday Afternoon

Scientific Session 4

12:00
Immune-based therapies for childhood cancer
Professor Crystal Mackall
Professor, Pediatrics & Medicine; Associate Director, Stanford Cancer Institute, Stanford Medical School, Stanford, CA, USA


13.30
Emerging approaches in melanoma immunotherapy
Dr Christian Blank
Group Leader at the Division of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands


16.10
Ongoing development of checkpoint trials
Dr James Larkin
Consultant Medical Oncologist, The Royal Marsden Hospital, London, UK


ACI is supported by sponsorship from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.